Early data from the LuPIN trial in men with mCRPC

Posted on July 16, 2019 by Sitemaster

A lot of people are hopeful that treatment with a new form of targeted nuclear radiation therapy — lutetium-177 PSMA 617 (177Lu PSMA) — will be able to significantly extend survival of men with metastatic, castration-resistant prostate cancer (mCRPC) … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , | 1 Comment »

ADT is associated with risk for Alzheimer’s and dementia in largest study to date

Posted on July 16, 2019 by Sitemaster

According to the newest and largest known analysis of data currently available, there is a small but statistically significant association between treatment with androgen deprivation therapy (ADT) and increase in risk for Alzheimer’s disease and/or dementia over time. … READ MORE …

Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: , , , , , | 10 Comments »

Patient-reported outcomes and the management of prostate cancer

Posted on July 3, 2019 by Sitemaster

Andrew Vickers, PhD, who works at the Memorial Sloan-Kettering Cancer Center in New York, is not a physician. He is a statistician and a research methodologist. And he is a member of the Scientific Advisory Board to The “New” Prostate Cancer InfoLink. … READ MORE …

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , | 2 Comments »

Evidence for dose escalation in adjuvant/salvage radiation

Posted on June 30, 2019 by Sitemaster

It is well known that prostate cancer is relatively radio-resistant compared to other kinds of cancer. … READ MORE …

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: , , , , | Leave a comment »

Patient satisfaction and the management of localized prostate cancer

Posted on June 14, 2019 by Sitemaster

A recent paper from a large Swedish research group has addressed patient satisfaction and the management of localized prostate cancer — with a specific, inclusive focus on the satisfaction of men initially managed on active surveillance. … READ MORE …

Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: , , , , | 2 Comments »

Gallium-68 PSMA vs. fluorine-18 fluciclovine PET/CT scans

Posted on June 3, 2019 by Sitemaster

According to a presentation given yesterday at the ASCO meeting here in Chicago, PET/CT scanning with 68Ga-PSMA-11 is more accurate than 18F-fluciclovine PET/CT at detecting recurrent prostate cancer in men with early biochemical recurrence following radical prostatectomy. … READ MORE …

Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: , , , , , | 11 Comments »

Data from the TAXOMET trial also presented at ASCO

Posted on June 3, 2019 by Sitemaster

Data from a small, Phase II, French trial known as the TAXOMET trial were also presented yesterday at the ASCO meeting. … READ MORE …

Filed under: Living with Prostate Cancer, Management, Treatment | 5 Comments »

« Previous Page — Next Page »